Genentech warns of anemia in Avastin combo trial

 14.07.2008 17:01   reuters.com

WASHINGTON (Reuters) - Genentech Inc has warned doctors about a type of anemia seen in patients treated with the company's blockbuster cancer drug Avastin in combination with Pfizer Inc's Sutent in a clinical trial, U.S. regulators said in a notice issued on Monday.

World Health & Beauty